EMA Review of Belantamab Mafodotin (Blenrep) for the Treatment of Adult Patients with Relapsed/Refractory Multiple Myeloma

On August 25, 2020, a marketing authorization valid through the European Union was issued for belantamab mafodotin monotherapy for the treatment of multiple myeloma (MM) in adult patients who have received at least four prior therapies, whose disease is refractory to at least one proteasome inhibito...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Oncologist
Principais autores: Tzogani, Kyriaki, Penttilä, Karri, Lähteenvuo, Johanna, Lapveteläinen, Tuomo, Lopez Anglada, Lucía, Prieto, Carolina, Garcia‐Ochoa, Blanca, Enzmann, Harald, Gisselbrecht, Christian, Delgado, Julio, Pignatti, Francesco
Formato: Artigo
Idioma:Inglês
Publicado em: John Wiley & Sons, Inc. 2020
Assuntos:
Regulatory Issues: EMA
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC7794172/
https://ncbi.nlm.nih.gov/pubmed/33179377
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/onco.13592
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registros relacionados